» Articles » PMID: 12023553

Functional Selectivity of Dopamine Receptor Agonists. II. Actions of Dihydrexidine in D2L Receptor-transfected MN9D Cells and Pituitary Lactotrophs

Overview
Specialty Pharmacology
Date 2002 May 23
PMID 12023553
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

D(2)-like dopamine receptors mediate functional changes via activation of inhibitory G proteins, including those that affect adenylate cyclase activity, and potassium and calcium channels. Although it is assumed that the binding of a drug to a single isoform of a D(2)-like receptor will cause similar changes in all receptor-mediated functions, it has been demonstrated in brain that the dopamine agonists dihydrexidine (DHX) and N-n-propyl-DHX are "functionally selective". The current study explores the underlying mechanism using transfected MN9D cells and D(2)-producing anterior pituitary lactotrophs. Both dopamine and DHX inhibited adenylate cyclase activity in a concentration-dependent manner in both systems, effects blocked by D(2), but not D(1), antagonists. In the MN9D cells, quinpirole and R-(-)-N-propylnorapomorphine (NPA) also inhibited the K(+)-stimulated release of [(3)H]dopamine in a concentration-responsive, antagonist-reversible manner. Conversely, neither DHX, nor its analogs, inhibited K(+)-stimulated [(3)H]dopamine release, although they antagonized the effects of quinpirole. S-(+)-NPA actually had the reverse functional selectivity profile from DHX (i.e., it was a full agonist at D(2L) receptors coupled to inhibition of dopamine release, but a weak partial agonist at D(2L) receptor-mediated inhibition of adenylate cyclase). In lactotrophs, DHX had little intrinsic activity at D(2) receptors coupled to G protein-coupled inwardly rectifying potassium channels, and actually antagonized the effects of dopamine at these D(2) receptors. Together, these findings provide compelling evidence for agonist-induced functional selectivity with the D(2L) receptor. Although the underlying molecular mechanism is controversial (e.g., "conformational induction" versus "drug-active state selection"), such data are irreconcilable with the widely held view that drugs have "intrinsic efficacy".

Citing Articles

Structural basis of efficacy-driven ligand selectivity at GPCRs.

Powers A, Pham V, Burger W, Thompson G, Laloudakis Y, Barnes N Nat Chem Biol. 2023; 19(7):805-814.

PMID: 36782010 PMC: 10299909. DOI: 10.1038/s41589-022-01247-5.


Dopamine D receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, behavior, and neurophysiology.

Yang Y, Lewis M, Huang X, Dokholyan N, Mailman R Int J Biochem Cell Biol. 2022; 148:106235.

PMID: 35688404 PMC: 10266066. DOI: 10.1016/j.biocel.2022.106235.


Functional Selectivity of Dopamine D Receptor Signaling: Retrospect and Prospect.

Yang Y Int J Mol Sci. 2021; 22(21).

PMID: 34769344 PMC: 8584964. DOI: 10.3390/ijms222111914.


D, not D, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa.

Mailman R, Yang Y, Huang X Eur J Pharmacol. 2020; 892:173760.

PMID: 33279520 PMC: 7861126. DOI: 10.1016/j.ejphar.2020.173760.


Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines.

Front Pharmacol. 2019; 10:418.

PMID: 31024325 PMC: 6460767. DOI: 10.3389/fphar.2019.00418.